Abstract 121P
Background
Colorectal cancer (CRC) is one of the most common malignancies, which has high morbidity and mortality rates globally. Recent studies have shown that tumor immune microenvironment (TIME) plays an important role in the development of CRC. Regulatory T cells (Tregs), a group of immunosuppressive cells, is significant in TIME. However, the role of Tregs in CRC is still controversial.
Methods
We used single-cell RNA sequencing (scRNA-seq) to profile the immune landscape of CRC, aiming to identify key subtype of Treg in the TIME that contribute to the development of CRC. The role of this key subtype of Treg in CRC prognosis was investigated by survival analyses of data from The Cancer Genome Atlas (TCGA) and multiple immunohistochemistry (mIHC) data of colorectal tumor samples collected from Zhongshan Hospital of Fudan University.
Results
Through scRNA-seq of tumor lesions of 13 patients with CRC, we found a new subtype of Treg, which was presented with high expression of baculoviral IAP repeat containing 3 (BIRC3). We confirmed its existence in colorectal cancer lesions by mIHC. Survival analysis of mIHC data from Zhongshan Hospital showed that Treg with high expression of BIRC3 was related with worse overall survival (OS) in CRC patients (P = 0.015). Survival analysis of TCGA database also reached a consistent result (P = 0.024). Multivariate analyses of both mIHC and TCGA data suggested that high expression of BIRC3 in Treg cells was an independent influencing factor for OS of CRC.
Conclusions
This study reveals that BIRC3 is expressed by Treg cells. High expression of BIRC3 in Treg cells indicates negative prognosis in CRC patients, which may provide a rationale for subsequent drug development and CRC management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract